智通财经网·2025-09-15 10:00Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, which is developed in-house and targets upper gastrointestinal bleeding caused by various factors excluding tumors and esophageal or gastric variceal bleeding [1][2]. Group 1: Product Approval - The approval of Famotidine Injection enhances the company's product portfolio [1]. - The drug is specifically indicated for upper gastrointestinal bleeding due to peptic ulcers and other causes [1]. Group 2: Financial Investment and Market Potential - The company has invested approximately RMB 7.67 million in the research and development of this drug as of August 2025 [2]. - The projected sales revenue for Famotidine Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is estimated to be around RMB 1.377 billion in 2024 [2].